stockrow
Saturday 7 November 2026
Export NVOS’s income statement to Excel — free account
Novo Integrated Sciences, Inc.
NVOS Healthcare Medical Care Facilities
Novo Integrated Sciences, Inc.’s revenue for fiscal 2024 (year ended August 2024) was $13.3 million, up 5.75% from fiscal 2023.
0.00
0.00
NaN
Follow NVOS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to August
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Trend | 10 yrs | 2025e | 2026e | 2027e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | 7 | 8 | 9 | 9 | 8 | 9 | 12 | 13 | 13 | +8.0% | — | — | — | — | |
| Gross margin, % | — | 34.93 | 37.39 | 38.49 | 37.35 | 38.91 | 41.08 | 40.89 | 39.39 | 43.19 | +8.3 pt | ||||||
| EBT | — | 0 | (1) | (2) | 0 | (5) | (4) | (33) | (13) | (16) | +77.3% | ||||||
| EBT margin, % | — | 0.00 | (7.96) | (23.80) | (4.28) | (62.64) | (48.05) | (281.72) | (105.55) | (121.32) | (121.3) pt | ||||||
| Net income | — | 0 | (1) | (2) | 0 | (5) | (4) | (33) | (13) | (16) | +77.3% | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.45 | 0.43 | 0.43 | 3.41 | 3.76 | 4.03 | 1.24 | 0.74 | n/m | |||||
| Earnings | — | (0.07) | (0.04) | (0.10) | (0.02) | (2.14) | (1.80) | (11.30) | (1.30) | (0.89) | +36.5% | ||||||
| Cash flow | — | (0.05) | (0.05) | (0.04) | (0.04) | (0.19) | (0.41) | (2.02) | (0.22) | (0.28) | +24.4% | ||||||
| Capex | — | 0.00 | 0.00 | (0.01) | 0.00 | (0.01) | (0.10) | (0.07) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | (0.05) | (0.05) | (0.05) | (0.04) | (0.20) | (0.52) | (2.08) | (0.23) | (0.28) | +24.4% | ||||||
| Book value | — | 0.02 | (0.24) | 0.01 | 1.18 | 12.84 | 17.68 | 7.57 | 2.41 | 0.81 | +56.6% | ||||||
| Shares, m | — | 2 | 18 | 21 | 22 | 2 | 2 | 3 | 10 | 18 | +29.8% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | 0.00 | 62.48 | 233.37 | 85.34 | 11.72 | 4.85 | 4.13 | 1.13 | 0.39 | 44.8 | ||||||
| P/B | — | 0.00 | 0.00 | 12,012.09 | 31.48 | 3.12 | 1.03 | 2.20 | 0.58 | 0.36 | 1,339.0 | ||||||
| EV/Sales | — | 0.00 | 63.53 | 233.97 | 85.38 | 11.59 | 5.10 | 4.49 | 1.20 | 0.41 | 45.1 | ||||||
| EV/FCF | — | 1,104.35 | (495.36) | (1,869.53) | (865.04) | (198.74) | (36.79) | (8.68) | (6.58) | (1.06) | (264.2) | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | 0 | (1) | (1) | (1) | 0 | (1) | (6) | (2) | (5) | +61.5% | |||||
| Capex | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (25.9%) | ||||||
| Free cash flow | — | 0 | (1) | (1) | (1) | 0 | (1) | (6) | (2) | (5) | +61.5% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | 0 | (1) | (1) | 1 | 2 | 3 | (8) | (4) | (9) | n/m | |||||
| Net debt | — | 0 | 4 | 2 | 1 | (1) | 2 | 9 | 1 | 0 | n/m | ||||||
| Shareholders’ equity | — | 0 | (4) | 0 | 26 | 30 | 44 | 22 | 24 | 15 | +103.2% | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | (11.14) | (26.45) | (41.10) | (2.12) | (14.53) | (9.17) | (63.89) | (34.58) | (47.76) | (36.6) pt | |||||
| ROIC | — | 0.00 | 0.00 | (44.19) | (1.88) | (9.33) | (5.93) | (50.20) | (21.09) | (42.44) | (42.4) pt | ||||||
| ROE | — | 4.69 | 34.85 | 102.44 | (3.05) | (17.84) | (12.16) | (99.77) | (56.78) | (82.67) | (87.4) pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | 0 | 61 | 86 | 70 | 110 | 172 | 206 | 230 | 264 | n/m | |||||
| Revenue/emp, $m | — | 0.00 | 0.13 | 0.10 | 0.13 | 0.07 | 0.05 | 0.06 | 0.05 | 0.05 | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Aug 2024 · latest quarter Aug 2024 · fundamentals updated 2 Nov 2026
Novo Integrated Sciences, Inc. vs peers in Medical Care Facilities (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BTMD biote Corp. | $37.4M | 6.6× | — (loss-making) | −9.48% (below 0%: shrinking) | n/m | −174.16% (below 0%: shrinking) | 65.38% | (7.93%) | Compare |
| PIII P3 Health Partners Inc. | $28.1M | — (loss-making) | — | +8.60% (above 0%: growing) | n/m | −272.24% (below 0%: shrinking) | 22.26% | 10.67% | Compare |
| DCGO DocGo Inc. | $24.1M | — (loss-making) | — (loss-making) | −8.70% (below 0%: shrinking) | n/m | −132.28% (below 0%: shrinking) | 30.52% | (24.41%) | Compare |
| CCM Concord Medical Services Holdings Limited | $10.0M | — (loss-making) | — (loss-making) | +37.65% (above 0%: growing) | n/m | −281.45% (below 0%: shrinking) | (13.15%) | 0.00% | Compare |
| AMS American Shared Hospital Services | $7.8M | — (loss-making) | 1.8× | +19.22% (above 0%: growing) | n/m | +195.82% (above 0%: growing) | 17.00% | (7.22%) | Compare |
| RHEP Adcare Health Systems Inc | $5.2M | 0.6× | — (loss-making) | +143.03% (above 0%: growing) | n/m | +224.45% (above 0%: growing) | 31.50% | (0.88%) | Compare |
| SYRA Syra Health Corp. | $1.1M | 14.7× | — | +51.50% (above 0%: growing) | n/m | +235.76% (above 0%: growing) | 46.34% | 11.73% | Compare |
| NVOS Novo Integrated Sciences, Inc. | $730.0K | — (loss-making) | — (loss-making) | −6.74% (below 0%: shrinking) | n/m | −111.85% (below 0%: shrinking) | 51.21% | (87.60%) | |
| NIVF NewGenIvf Group Limited | $610.0K | — | — | — | — | — | — | — | Compare |
| Median of peers | $8.9M | 6.6× | — | +19.22% | — | −132.28% | 30.52% | (0.88%) |
Pay and ownership Proxy statement filed 17 October 2024
Ownership
Directors and executive officers, together
10.40%
Robert Mattacchione
6.80%
ALMC-ASAP Holdings, Inc.
6.80%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement